Supplemental Table 1: Patient baseline characteristics and current status

	All subjects (n = 10)
Age (years), mean (SD)	
At diagnosis	*52.5 (19.6)*
Current age or at time of death	*56.5 (18.9)*
Female, n (%)	*8 (80.0%)*
Years of disease, mean (SD)	*3.9 (3.21)*
Expert classification, n (%)	
Classic DM	*5 (50.0%)*
Amyopathic DM	*3 (30.0%)*
Anti-synthetase syndrome	*2 (20.0%)*
Autoantibodies identified, n	
Anti-Jo1	*1*
Anti-PL12	*1*
Anti-SAE1	*1*
Anti-MDA5	*4*
Anti-TIF-1	*1*
Anti-Ro52	*6*
Negative MSA and MAA	*1*
Myositis antibody panel not done	*1*
Systems involved, n (%)	
Muscular	*6 (60.0%)*
Pulmonary	*5 (50.0%)*
Articular	*5 (50.0%)*
Cutaneous	*7 (70.0%)*
Previous therapies, mean (SD)	*3.90 (1.91)*
Rituximab, n (%)	*1 (10.0%)*
IVIG, n (%)	*4 (40.0%)*
Mycophenolate, n (%)	*7 (70.0%)*
Azathioprine, n (%)	*5 (50.0%)*
Methotrexate, n (%)	*8 (80.0%)*
Leflunomide, n (%)	*1 (10.0%)*
Tacrolimus, n (%)	*3 (30.0%)*
Hydroxychloroquine or Quinacrine, n (%)	*5 (50.0%)*
Tofacitinib, n (%)	*3 (30.0%)*
Cyclophosphamide, n (%)	*1 (10.0%)*
Currently on upadacitinib, n	*9*
As monotherapy, n (%)	*3 (33.3%)*
With concurrent treatment, n (%)	*6 (67.7%)*
Prednisone, n (%)	*3 (33.3%)*
IVIG, n (%)	*1 (11.1%)*

Mycophenolate, n (%)	*2 (22.2%)*
Methotrexate, n (%)	*3 (44.4%)*
Adverse events, total, n (%)	*1 (10.0%)*
Acneiform rash, n (%)	*1 (10.0%)*